Substance P and fibrotic diseases

被引：17

作者：

Peng, Lei ^{[1
]}

Agogo, George O. ^{[2
]}

Guo, Jianqiang ^{[1
]}

Yan, Ming ^{[3
]}

机构：

[1] Shandong Univ, Hosp 2, Dept Gastroenterol, Jinan, Shandong, Peoples R China

[2] Yale Univ, Med Sch, Dept Internal Med, New Haven, CT 06511 USA

[3] Shandong Univ, Qilu Hosp, Dept Hepatol & Gastroenterol, Jinan, Shandong, Peoples R China

来源：

NEUROPEPTIDES | 2019年 / 76卷

关键词：

Substance P; NK-1R; Fibrotic disease; EPITHELIAL WOUND CLOSURE; DOWN-REGULATES COLLAGEN; HAMSTER OVARY CELLS; MOLECULAR-MECHANISMS; IMMUNOREACTIVE NERVES; TACHYKININ RECEPTORS; HEPATIC-FIBROSIS; LIVER FIBROSIS; RAT; INJURY;

D O I：

10.1016/j.npep.2019.101941

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Substance P (SP) is an undecapeptide encoding the tachykinin 1 (TAC1) gene and belongs to the tachykinin family. SP is widely distributed in the central nervous system and the peripheral nervous system. SP is also produced by nonneuronal cells, such as inflammatory cells and endothelial cells. The biological activities of SP are mainly regulated through the high-affinity neurokinin 1 receptor (NK-1R). The SP/NK-1R system plays an important role in the molecular bases of many human pathophysiologic processes, such as pain, infectious and inflammatory diseases, and cancer. In addition, this system has been implicated in fibrotic diseases and processes such as wound healing, myocardial fibrosis, bowel fibrosis, myelofibrosis, renal fibrosis, and lung fibrosis. Recently, studies have shown that SP plays an important role in liver fibrosis and that NK-1R antagonists can inhibit the progression of fibrosis. NK-1R receptor antagonists could provide clinical solutions for fibrotic diseases. This review summarizes the structure and function of SP and its involvement in fibrotic diseases.

引用

页数：6

共 107 条

[1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].

Aguayo, A ;

Kantarjian, H ;

Manshouri, T ;

Gidel, C ;

Estey, E ;

Thomas, D ;

Koller, C ;

Estrov, Z ;

O'Brien, S ;

Keating, M ;

Freireich, E ;

Albitar, M .

BLOOD, 2000, 96 (06) :2240-2245

[2] Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines [J].

Barosi, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2954-2970

[3] Liver fibrosis [J].

Bataller, R ;

Brenner, DA .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) :209-218

[4] Stiffness after total knee arthroplasty [J].

Bong, MR ;

Di Cesare, PE .

JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS, 2004, 12 (03) :164-171

[5] Renal fibrosis: novel insights into mechanisms and therapeutic targets [J].

Boor, Peter ;

Ostendorf, Tammo ;

Floege, Juergen .

NATURE REVIEWS NEPHROLOGY, 2010, 6 (11) :643-656

[6] The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-β signaling [J].

Borkham-Kamphorst, Erawan ;

Schaffrath, Christian ;

Van de Leur, Eddy ;

Haas, Ute ;

Tihaa, Lidia ;

Meurer, Steffen K. ;

Nevzorova, Yulia A. ;

Liedtke, Christian ;

Weiskirchen, Ralf .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2014, 1843 (05) :902-914

[7] Arthrofibrosis is the result of a T cell mediated immune response [J].

Bosch, U ;

Zeichen, J ;

Skutek, M ;

Haeder, L ;

van Griensven, M .

KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY, 2001, 9 (05) :282-289

[8] Clinical Benefits of Intra-articular Anakinra for Arthrofibrosis [J].

Brown, Christopher A. ;

Toth, Alison P. ;

Magnussen, Bob .

ORTHOPEDICS, 2010, 33 (12)

[9] AMINO-ACID SEQUENCE OF SUBSTANCE P [J].

CHANG, MM ;

LEEMAN, SE ;

NIALL, HD .

NATURE-NEW BIOLOGY, 1971, 232 (29) :86-+

[10]

Colovic MD, 1999, EUR J HAEMATOL, V62, P155

← 1 2 3 4 5 6 7 8 9 10 →